SCHEMBL3252805

SCHEMBL3252805

O=C(Cl)CCc1cccc(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 2/20 0.55
PLAAT5 Q96KN8 2/20 0.55
PLAAT2 Q9NWW9 2/20 0.55
PLAAT4 Q9UL19 2/20 0.55
TAAR1 Q96RJ0 4/20 0.55
ALDH1A1 P00352 3/20 0.54
KMT2A Q03164 2/20 0.54
HTR3E A5X5Y0 1/20 0.51
HTR3B O95264 1/20 0.51
HTR3A P46098 1/20 0.51
HTR3D Q70Z44 1/20 0.51
HTR3C Q8WXA8 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 1/20 0.51
HPGD P15428 1/20 0.51
CHRM2 P08172 1/20 0.50
CHRM1 P11229 1/20 0.50
CHRM3 P20309 1/20 0.50
FFAR1 O14842 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8301337 0.89 PLAAT3 (0.58) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL10980509 0.88 KEAP1 (0.46) PLAAT3PLAAT5PLAAT2PLAAT4ALDH1A1
SCHEMBL19612688 0.87 NAAA (0.56) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL7332799 0.86 TAAR1 (0.57) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL19612671 0.86 NAAA (0.56) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL80581 0.85 ALDH1A1 (0.67) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL2473717 0.83 HTR3E (0.59) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL30572312 0.83 HTR3E (0.59) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL1848 0.83 ALDH1A1 (0.60) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
Hydrochloric Acid SCHEMBL31606746 0.81 HTR3E (0.57) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2025-09-02 US disclosed
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 EP disclosed
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2024-04-30 US disclosed
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2024-04-11 US disclosed
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 WO disclosed
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-10-26 US disclosed
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-10-26 US disclosed
EP-4192828-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS Nura Bio, Inc. (US) 2023-06-14 EP disclosed
CN-113527075-B Preparation method for synthesizing 5-chloro-1-indanone by one-step method 佳尔科生物科技南通有限公司 2022-10-21 CN disclosed
CN-112939755-B Novel process for preparing 5-chloro-2, 3-dihydro-1-indanone 南开沧州渤海新区绿色化工研究有限公司 2022-06-21 CN disclosed
US-6664111-B2 The detector is a solid polymeric matrix, e.g., siloxane, modified by a luminescent platinum group metal phenanthroline chelate complex which is quenchable by oxygen; blood and tissue samples; medical diagnosis; compact; lightweight 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
US-20030199692-A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. 2003-10-23 US disclosed
US-20030099574-A1 Fluorescence based oxygen sensor systems 3M INNOVATIVE PROPERTIES COMPANY 2003-05-29 US disclosed
WO-2003019179-A1 FLUORESCENCE BASED OXYGEN SENSOR SYSTEMS 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-03-06 WO disclosed
EP-1189881-A4 PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS TEXAS BIOTECHNOLOGY CORP (US) 2002-11-27 EP disclosed
CN-1370143-A Propionic acid derivatives inhibiting the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORP (US) 2002-09-18 CN disclosed
WO-2000068188-A9 PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS TEXAS BIOTECHNOLOGY CORP (US) 2002-08-29 WO disclosed
EP-1213288-A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-06-12 EP disclosed
EP-1189881-A1 PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-03-27 EP disclosed
WO-2000068188-A1 PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 PLAAT3 1471/4885PLAAT5 1656/4885PLAAT2 1068/4885
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 PLAAT3 1471/4885PLAAT5 1656/4885PLAAT2 1068/4885
US-20030199692-A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, FN1 PLAAT3 696/4885PLAAT5 676/4885PLAAT2 1072/4885
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 PLAAT3 1471/4885PLAAT5 1656/4885PLAAT2 1068/4885
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 PLAAT3 1471/4885PLAAT5 1656/4885PLAAT2 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.